Combination Therapy with Normobaric Oxygen (NBO) Plus Thrombolysis in Experimental Ischemic Stroke

DSpace/Manakin Repository

Combination Therapy with Normobaric Oxygen (NBO) Plus Thrombolysis in Experimental Ischemic Stroke

Citable link to this page

 

 
Title: Combination Therapy with Normobaric Oxygen (NBO) Plus Thrombolysis in Experimental Ischemic Stroke
Author: Fujiwara, Norio; Murata, Yoshihiro; Egi, Yasuhiro; Arai, Ken; Lu, Jie; Wu, Ona; Singhal, Aneesh B.; Lo, Eng H.

Note: Order does not necessarily reflect citation order of authors.

Citation: Fujiwara, Norio, Yoshihiro Murata, Ken Arai, Yasuhiro Egi, Jie Lu, Ona Wu, Aneesh B. Singhal, and Eng H. Lo. 2009. Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. BMC Neuroscience 10: 79.
Full Text & Related Files:
Abstract: Background: The widespread use of tissue plasminogen activator (tPA), the only FDA-approved acute stroke treatment, remains limited by its narrow therapeutic time window and related risks of brain hemorrhage. Normobaric oxygen therapy (NBO) may be a useful physiological strategy that slows down the process of cerebral infarction, thus potentially allowing for delayed or more effective thrombolysis. In this study we investigated the effects of NBO started simultaneously with intravenous tPA, in spontaneously hypertensive rats subjected to embolic middle cerebral artery (MCA) stroke. After homologous clot injection, animals were randomized into different treatment groups: saline injected at 1 hour; tPA at 1 hour; saline at 1 hour plus NBO; tPA at 1 hour plus NBO. NBO was maintained for 3 hours. Infarct volume, brain swelling and hemorrhagic transformation were quantified at 24 hours. Outcome assessments were blinded to therapy. Results: Upon clot injection, cerebral perfusion in the MCA territory dropped below 20% of pre-ischemic baselines. Both tPA-treated groups showed effective thrombolysis (perfusion restored to nearly 100%) and smaller infarct volumes (379 ± 57 mm3 saline controls; 309 ± 58 mm3 NBO; 201 ± 78 mm3 tPA; 138 ± 30 mm3 tPA plus NBO), showing that tPA-induced reperfusion salvages ischemic tissue and that NBO does not significantly alter this neuroprotective effect. NBO had no significant effect on hemorrhagic conversion, brain swelling, or mortality. Conclusion: NBO can be safely co-administered with tPA. The efficacy of tPA thrombolysis is not affected and there is no induction of brain hemorrhage or edema. These experimental results require clinical confirmation.
Published Version: doi:10.1186/1471-2202-10-79
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714858/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:4728741
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters